« Back

Vaccines and Other Preventative Strategies

In an effort to advance strategies to prevent infectious diseases, faculty members within the Department of Pediatrics are actively engaged in the development and implementation of a variety of prevention strategies. Their research focuses on developing new vaccines, creating effective topical microbicides (products that can be used topically to prevent the transmission of sexually transmitted infections), and fostering attitudes and developing systems that promote the timely delivery and use of these methods.



  • Microbicides and toll-like receptors Sexually Transmitted Infections and Topical Microbicides . NIH/NIAID. Pyles 25%, 2005-2010.Cooperative Research Center GrantPI: David Martin, LSU-HSC, New Orleans. $858,210.
  • Protection of genital mucosa and ganglia against HSV-2. NIAID/ NIH. G. Milligan, Principal Investigator, 33% effort, 9/01/05-02/28/10, Total Costs: $1,189,125.
  • Microbicides; Developmental Context of Acceptability. National Institutes of Health, R01, Rosenthal, Principal Investigator, 2000 - 2006, $1,987,808.
  • Gulf South Sexually Transmitted Infections-Topical Microbicides Cooperative Research Center. National Institute of Allergy and Infectious Diseases Grant No. U19 AI61972. Stanberry, Co-Principal Investigator with Dr. D. Martin, Louisiana State University, New Orleans, LA.2004-2010.
  • Microbicide Design and Development Teams. PI: T. McCarthy. National Institute of Allergy and Infectious Diseases Grant No N01-AI-50042. Stanberry - Member of the Protocol Steering Committee (Consultant). 2005-2010.
  • Evaluation of Colposcopy for use in Vaginal Product Development, National Institute of Child Health and Human Development. N01-HD-5-3407. Stanberry - Principal Investigator. 2005-2008
  • Studies of single chain antibodies for immunotherapy of tumors and persistent virus infections. Gillson-Longenbaugh Foundation (Houston) Principal Investigator Anthony Simmons 2004-2007

Relevant Publications

  • Auslander BA, Rosenthal SL, Succop PA, Mills LM, Stanberry LR, Berstein DI (2005). Gender-specific predictors of genital herpes vaccine acceptance in a college population. International Journal of STD and AIDS: 16; 27-30.
  • Short MB. Rupp R. Stanberry LR. Rosenthal SL. Parental acceptance of adolescent vaccines within school-based health centres. Herpes. 12:23-7, 2005.
  • Stanberry LR. Spruance SL. Cunningham AL. Bernstein DI. Mindel A. Sacks S. Tyring S. Aoki FY. Slaoui M. Denis M. Vandepapeliere P. Dubin G. GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. New England Journal of Medicine. 347:1652-61, 2002 Nov 21.
  • Rosenthal, S.L. (2005). Protecting their adolescents from harm: Parental views on STI vaccination. Journal of Adolescent Health Care. 37, 177-178.
  • Rupp R. Rosenthal SL. Stanberry LR. Pediatrics and herpes simplex virus vaccines. Seminars in Pediatric Infectious Diseases. 16:31-7, 2005 Jan.
  • Lambert KC, Curran EM, Judy BM, Milligan GN, Lubahn DB, Estes DM. ERa deficiency in macrophages results in increased stimulation of CD4+ T cells while E2 acts through ERa to increase IL-4 and GATA-3 expression in CD4+ T cells independent of antigen presentation. Journal of Immunology 175: 5716-5723, 2005.
  • Bourne, N, Milligan, GN, Stanberry, LR, Stegall, R and Pyles, RB. Immunization with a Herpes Simplex Virus Type 2 (HSV-2) Glycoprotein-D-Adjuvant Vaccine Reduces the Quantity but not Frequency of Viral Shedding into the Genital Tract in Guinea Pigs That Become Infected. Journal of Infectious Diseases 192:2117-23. Epub 2005 Nov 11.
  • Pyles, RB., Higgins, D, Chalk, CL, Zalar, A, Brown, C, Van Nest, G, and Stanberry, LR. 2002. Use of Immunostimulatory Sequence-Containing Oligonucleotides as Topical Therapy for Genital Herpes Simplex Virus Type 2 Infection. Journal of Virology. 76:11387-11396.
  • Milligan, G. N., Meador, M. G., Chu, C-F., Young, C. G., Martin, T. L., and Bourne , N. Long-term presence of virus-specific plasma cells in sensory ganglia and spinal cord following intravaginal inoculation of herpes simplex virus type 2 (HSV-2). J. Virol. 79: 11537-11540. 2005.
  • Chen J, Dave SK, Simmons A Prevention of genital herpes in a guinea pig model using a glycoprotein D-specific single chain antibody as a microbicide Virology Journal 1:11. 2004.
  • Simmons A, Whitehead RP, Kolokoltsov AA and Davey RA. Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro. Virology Journal 3: 8 2006.